Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ProceedingsPOSTER VIEWING PRESENTATIONS
Open Access

BREATHOMICS IN SYSTEMIC LUPUS ERYTHEMATOSUS: UNCOVERING NONINVASIVE MARKERS OF DISEASE ACTIVITY AND FATIGUE

Martina Iacubino, Ioannis Parodis, Lorenzo Rocco, Alexandre Voskuijl, Marta Alarcón-Riquelme, Liam Grimmet, Matt Kerr, Chiara Bellocchi, Barbara Vigone, Alessandro Santaniello and Lorenzo Beretta
The Journal of Rheumatology May 2025, 52 (Suppl 1) 92; DOI: https://doi.org/10.3899/jrheum.2025-0390.PV024
Martina Iacubino
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Referral Center for Systemic Autoimmune Diseases, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioannis Parodis
2Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorenzo Rocco
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Referral Center for Systemic Autoimmune Diseases, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Voskuijl
3Amstrerdam UMC, Amsterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Alarcón-Riquelme
4GENyO, Center for Genomics and Oncological Research Pfizer/University of Granada, Department of Medical Genomics, Granada, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liam Grimmet
5Owlstone Medical Ltd, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matt Kerr
5Owlstone Medical Ltd, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiara Bellocchi
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Referral Center for Systemic Autoimmune Diseases, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Vigone
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Referral Center for Systemic Autoimmune Diseases, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Santaniello
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Referral Center for Systemic Autoimmune Diseases, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorenzo Beretta
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Referral Center for Systemic Autoimmune Diseases, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Previous
Loading

Abstract

PV024 / #545

Poster Topic: AS04 - Biomarkers

Background/Purpose 3TR (taxonomy, treatment, targets and remission) aims to provide insights into the mechanisms of response and nonresponse to treatment in autoimmune diseases. The lupus arm of 3TR focuses on identifying reliable biomarkers that could serve as indicators of disease or disease severity, and molecular processes that determine patients’ response to medication. Volatile organic compounds (VOCs) can be generated by metabolic processes in the body being impacted by disease pathology. VOCs diffuse from their point of origin into the blood to be emitted through breath, providing a potential noninvasive method to assess whole-body metabolism.

Methods Sixty patients (30 SLE and 30 age- and sex-matched healthy controls) were recruited to a single-site, case-control observational study. Breath VOC sampling was performed using the ReCIVA® breath sampler, linked to a clean air supply (CASPER®). Collected samples were analyzed by thermal desorption gas chromatography-mass spectrometry (TD-GC-MS) by Owlstone Medical. VOCs were chemically identified in alignment with the Metabolomics Standards Initiative (MSI) criteria, with blank air samples analyzed to discern VOCs genuinely present in patients’ breath. Univariate analyses were performed by linear regression modeling for categorical variables and by Spearman’s rank correlation coefficient for continuous variables, including physician/patient global assessments (PhGA/PGA) and FACIT-F scores.

Results Patients had a median disease duration of 14 years (IQR: 6–21), with a mean (SD) SLEDAI-2K score of 3.6 (3.3). Twenty subjects (70%) were in LLDAS and 14 (46.7%) in DORIS remission. The mean PhGA and PGA scores were 19.7 (19) and 40.3 (33.7). Fourteen patients (46.7%) tested positive for anti-dsDNA. The mean serum C3 and C4 levels were 90 (20) and 8.6 (9.5) mg/dL, with 17 patients (56.7%) hypocomplementemic. The mean FACIT-F score was 37.9 (11.9). After quality control, 1,433 VOCs were observed. Of these, 539 were classified as “on-breath,” appearing at significantly higher levels than background. VOC identities were assigned based on pure analytical standards or matches to third-party databases, with on-breath statistically significant VOCs further interpreted for their biological relevance. Three main themes emerged from the analysis (Figure). First, a strong link was found between SLE and gut microbiome, with significant decreases in gut microbiome fermentation products (eg, 2-butanol and 1-propanol) in SLE. Additionally, elevated levels of 2,3-butanediol correlated with greater disease severity. Notably, differences in gut microbiome products were also observed in SLE according to complement levels. Second, there was a positive correlation between VOCs with potential links to oxidative stress and inflammation (ie, cyclopentene, 3-methyl-2-pentene, and 2-methyl-1-butene) and disease severity indicators, including SLEDAI-2K, LLDAS, DORIS remission and both PhGA and PGA. Third, there was evidence of a correlation between an altered gut microbiome and fatigue. Results pointed toward a decrease of sulfate-reducing bacteria that may eventually promote inflammation via a loss of degradation of cyclopentene, coupled with a syntropic compensatory production of butyrate.

  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

Conclusions These data demonstrate, for the first time, the potential of breath-based VOC analysis in detecting pathophysiological changes in SLE patients. They align with recent findings that highlight gut microbiome dysbiosis as central in SLE and suggest a potential link with complement levels. Our data demonstrate the functional nature of gut dysbiosis with significant correlation with fatigue. These data reveal possible markers of inflammation, which correlate with disease severity and patient’s perception of fatigue and offer an exciting prospect for noninvasive disease assessment. Future work should focus on validating these markers and their associations with additional inflammatory indicators.

  • Copyright © 2025 by the Journal of Rheumatology

This is an Open Access article, which permits use, distribution, and reproduction, without modification, provided the original article is correctly cited and is not used for commercial purposes.

Previous
Back to top

In this issue

The Journal of Rheumatology
Vol. 52, Issue Suppl 1
21 May 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
BREATHOMICS IN SYSTEMIC LUPUS ERYTHEMATOSUS: UNCOVERING NONINVASIVE MARKERS OF DISEASE ACTIVITY AND FATIGUE
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BREATHOMICS IN SYSTEMIC LUPUS ERYTHEMATOSUS: UNCOVERING NONINVASIVE MARKERS OF DISEASE ACTIVITY AND FATIGUE
Martina Iacubino, Ioannis Parodis, Lorenzo Rocco, Alexandre Voskuijl, Marta Alarcón-Riquelme, Liam Grimmet, Matt Kerr, Chiara Bellocchi, Barbara Vigone, Alessandro Santaniello, Lorenzo Beretta
The Journal of Rheumatology May 2025, 52 (Suppl 1) 92; DOI: 10.3899/jrheum.2025-0390.PV024

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
BREATHOMICS IN SYSTEMIC LUPUS ERYTHEMATOSUS: UNCOVERING NONINVASIVE MARKERS OF DISEASE ACTIVITY AND FATIGUE
Martina Iacubino, Ioannis Parodis, Lorenzo Rocco, Alexandre Voskuijl, Marta Alarcón-Riquelme, Liam Grimmet, Matt Kerr, Chiara Bellocchi, Barbara Vigone, Alessandro Santaniello, Lorenzo Beretta
The Journal of Rheumatology May 2025, 52 (Suppl 1) 92; DOI: 10.3899/jrheum.2025-0390.PV024
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • LUPUS AND NUTRITION -THE FIRST STEP TO CONTROL YOUR FLARES?
  • FACTORS ASSOCIATED WITH EFFICACY OF BELIMUMAB IN DIFFERENT JOINT AND SKIN PHENOTYPES OF SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY DATA FROM THE MULTICENTER BERLISS-NEJS STUDY
  • RITUXIMAB IN REFRACTORY SLE: 10 YEARS AFTER
Show more POSTER VIEWING PRESENTATIONS

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire